Overview

This trial is active, not recruiting.

Condition acute coronary syndromes
Sponsor AstraZeneca
Start date December 2014
End date April 2017
Trial size 3000 participants
Trial identifier NCT02305680, D1843R00049, NIS-CCN-XXX-2014/1

Summary

This study is to describe the long-term antithrombotic management patterns in a real-life setting for patients hospitalized with an acute coronary syndrome in China.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Measure
Long-term antithrombotic management patterns in a real-life setting by assessing the medication and treatment prescribed by physicians
time frame: From 2 years after the acute coronary syndrome index event, assessed up to 5 years

Secondary Outcomes

Measure
Clinical outcomes by record the number and type of cardiovascular and non-cardiovascular events
time frame: From 2 years after the acute coronary syndrome index event, assessed up to 5 years
Health care resource consumption and related costs by assessing the detail hospitalization and outpatient cost.
time frame: From 2 years after the acute coronary syndrome index event, assessed up to 5 years
Quality of life by assessing EQ-5D questionnaire.
time frame: 2 years,2.5years,3years,3.5years,4years,4.5years,5years after the acute coronary syndrome index event

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: 1. Written informed consent has been provided. 2. Contact Order Form has been provided 3. Aged 18 years or older. 4. Enrolled in EPICOR Asia study and completed the 2 year follow-up. Exclusion Criteria: 1. Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the complete follow up of the patient (e.g. tourist, non-native speaker or does not understand the local language, psychiatric disturbances, alcohol or drug abuse). 2. Already included in the EPICOR Asia-China Extension observational study. 3. Presence of serious/severe co-morbidities in the opinion of the investigator which may limit short term (i.e. 6 month) life expectancy. 4. Current participation in an interventional clinical trial. 5. Patients receiving ticagrelor beyond 12 months and other off label use.

Additional Information

Official title EPICOR Asia-China Extension. Long-term Follow-up of antithrombotIc Management Patterns in Acute Coronary Syndrome Patients in Asia-China Extension
Principal investigator Yong Huo, Doctor
Description This study is to describe the long-term (3 to 5 years after the acute coronary syndrome index event) antithrombotic management patterns in a real-life setting for patients hospitalized with an acute coronary syndrome (i.e. ST-segment Elevation Myocardial Infarction, Non-ST-segment Elevation Myocardial Infarction, Unstable Angina) in China.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by AstraZeneca.